Clinical trials: Adjuvant Treatment
Breast Cancer, Cardiac Toxicity
Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00436566
- Testing
- trastuzumab, cyclophosphamide, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- Mayo Clinic
NSCLC
TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy
This study evaluates the preliminary efficacy and safety of adjuvant therapy with liquid tumor-infiltrating lymphocytes (L-TIL) in combination with tislelizumab in patients with resectable stage II-IIIB non-small cell lung cancer…
- Trial name
- NCT07330037
- Testing
- L-TIL cells injection, Tislelizumab
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Physical Activity, Breast Cancer
Study of Program Interest "Bouge" to Improve the Daily Physical Activity in Processings Treatment of Non-metastatic Breast Cancer
Evaluate the "Bouge" digital program (smartphone application) to increase the daily physical activity of breast cancer patients
- Conditions
- Physical Activity, Breast Cancer, Mobile Health Apps
- Trial name
- BOUGE CANCER (NCT03674515)
- Testing
- Smartphone equipped with application "bouge" = Coach group
- Where
- 2 sites in France
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University Hospital, Brest
Non-small Cell Lung Cancer
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.
- Trial name
- NAUTIKA1 (NCT04302025)
- Testing
- Alectinib, Entrectinib, Vemurafenib
- Where
- 38 sites in United States
- Volunteers
- 99 people
- Sponsor
- Genentech, Inc.
Covid19
Hyperbaric Oxygen as an Adjuvant Treatment for Patients With Covid-19 Severe Hypoxemia
The severity of COVID-19 is related to the level of hypoxemia, respiratory failure, how long it lasts and how refractory it is at increasing concentrations of inspired oxygen.
- Trial name
- NCT04477954
- Testing
- Hyperbaric Oxygen
- Where
- 3 sites in Argentina
- Volunteers
- 40 people
- Sponsor
- Asociación Argentina de Medicina Hiperbárica e Investigación
Community-acquired Pneumonia
Study of the Efficacy and Safety of Antioxidants Astaxanthin as an Adjuvant Therapy for Community Acquired Pneumonia Patients.
Community acquired pneumonia (CAP) is one of the most common and morbid conditions encountered in clinical practice, which causes serious morbidity worldwide.
- Trial name
- NCT06334874
- Testing
- Astaxanthin Oral Capsule
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Future University in Egypt
Bacterial Vaginosis (BV), Recurrent Bacterial Vaginosis
Evaluation of the Medical Device Vagitab - T as Adjuvant Therapy in Patients With Bacterial Vaginosis.
This clinical trial is looking at how well and safely the vaginal administration of Vagitab-T works . Vagitab-T is already on the market in several countries in Europe as a medical device.
- Trial name
- Vagitab (NCT06725888)
- Testing
- Vagitab -T vaginal tablets. Components: tyndallized probiotic L. plantarum HA-119, lactic acid, and xylo-oligosaccharides, lauryl glucoside, and macrogol 3350:
- Where
- Romania
- Volunteers
- 30 people
- Sponsor
- S.I.I.T. Srl
The Aim of the Study is to Evaluate the Efficacy of Photodynamic Therapy as an, Adjuvant Therapy on the Clinical Outcome of Patients With Desmoid Tumors After
Safety and Efficacy Study Using 5-ALA Oral Administration as an Adjuvant Therapy on the Rate of Local Tumor Recurrence in Patients Who Have Desmoids Tumors
The purpose of this study is to evaluate the efficacy of preoperative 5-ALA oral administration and subsequently intraoperative tumor bed phototherapy with red light laser, as an adjuvant therapy on the 3 years rate of local…
- Conditions
- The Aim of the Study is to Evaluate the Efficacy of Photodynamic Therapy as an, Adjuvant Therapy on the Clinical Outcome of Patients With Desmoid Tumors After, Surgical Resection
- Trial name
- NCT01898416
- Testing
- 5-AMINOLEVULINIC ACID (5-ALA), is a non fluorescent prodrug.
- Where
- 2 sites in Israel
- Volunteers
- 140 people
- Sponsor
- michal roll
Head & Neck Squamous Cell Carcinoma, Head & Neck Cancer
Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma
A Multicenter, Randomized, Controlled, Open-Label, Phase III Clinical Trial.To evaluate the efficacy and safety of postoperative radiotherapy combined with Nimotuzumab followed by Benmelstobart in high-risk patients with head and…
- Conditions
- Head & Neck Squamous Cell Carcinoma, Head & Neck Cancer, Postoperative Adjuvant Treatment
- Trial name
- NCT07445048
- Testing
- Bemcentinib, Nimotuzumab, radiotherapy
- Where
- China
- Volunteers
- 370 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Lung Cancer
Vaccine Therapy Plus QS21 in Treating Patients With Small Cell Lung Cancer That Has Responded to Initial Therapy
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Biological therapies, such as QS21, use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00004249
- Testing
- QS21, keyhole limpet hemocyanin, polysialic acid
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Gastric Cancer
Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer
The purpose of this study is to find out whether treatment with Serplulimab combined with Trastuzumab and Chemotherapy will improve the survival of gastric cancer patients with stage II-III after surgery.
- Trial name
- NCT05975749
- Testing
- Serplulimab, Trastuzuma, Chemotherapy
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Fudan University
Breast Neoplasms
A Clinical Trial to Reduce Skin Burn Induced by Breast Radiotherapy Using Intensity Modulated Radiation Therapy (IMRT)
The purpose of this study is to determine whether the use of a 3D missing tissue compensation radiation technique during a standard adjuvant breast radiotherapy delivering a dose of 50Gy in 25 treatments could reduce…
- Trial name
- NCT00187343
- Testing
- Breast IMRT
- Where
- 2 sites in Canada
- Volunteers
- 340 people
- Sponsor
- Sunnybrook Health Sciences Centre
Liver Cancer
Evaluation of Cytokine-induced Killer (CIK) Cells as Therapy or Adjuvant Treatment for Advanced HCC
Hepatocellular carcinoma (HCC) is the fifth most common malignancy in the world and the third most common cause of cancer-related deaths complicating liver cirrhosis in most cases.
- Trial name
- NCT02568748
- Testing
- CIK, TACE
- Where
- Egypt
- Volunteers
- 20 people
- Sponsor
- Sherief Abd-Elsalam
Nasopharyngeal Carcinoma
Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma
To estimate the efficacy and safety of tislelizumab for stage IVA locally advanced nasopharyngeal carcinoma combined with induction chemotherapy and concurrent chemoradiotherapy, followed by maintenance therapy
- Trial name
- NCT05448885
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Urothelial Carcinoma Bladder, Bladder Cancer
Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer
The primary objective of this Phase I study is to establish the safety of adjuvant concurrent immunotherapy and radiation therapy for urothelial bladder cancer.
- Trial name
- NCT06586255
- Testing
- Concurrent Immunotherapy and Radiation Therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Cancer
Effect of a Program of Physical Activity and Nutritional Therapeutic Education in Breast Cancer Patients
This multicenter randomized controlled trial aims to evaluate the effect of a tailored program of physical activity and nutritional therapeutic education on clinical, psychological and sociological factors in breast cancer…
- Trial name
- APAD2 (NCT04109326)
- Testing
- APAD
- Where
- 8 sites in France
- Volunteers
- 360 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
This randomized phase II/III trial studies docetaxel, antiandrogen therapy, and radiation therapy to see how well it works compared with antiandrogen therapy and radiation therapy alone in treating patients with prostate cancer…
- Conditions
- Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
- Trial name
- NCT03070886
- Testing
- Bicalutamide, Degarelix, Docetaxel
- Where
- 313 sites in United States, Canada and 1 more
- Volunteers
- 612 people
- Sponsor
- NRG Oncology
Peanut Allergy
Adjuvant Treatment With Abatacept to Promote Remission During Peanut Oral Immunotherapy
This is a phase 2a, multi-center, randomized and double-blind placebo-controlled trial comparing 24 weeks of abatacept versus placebo used as adjuvant to oral immunotherapy to induce remission in adolescents and adults with…
- Trial name
- ATARI (NCT04872218)
- Testing
- Abatacept, Peanut oral immunotherapy
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- Philippe Bégin
Adjuvant Treatment
Adjuvant Treatment of Digestive Tract Tumors
To evaluate the 3-year Disease-free survival rate(DFSR) of patients with locally advanced gastric cancer and colorectal cancer treated with anlotinib combined with adjuvant chemotherapy.
- Trial name
- ATDTT (NCT05742620)
- Testing
- anlotinib+CAPEOX/SOX
- Volunteers
- 100 people
- Sponsor
- Xijing Hospital
Colorectal Cancer
Combination Chemotherapy With or Without Irinotecan in Treating Patients With Stage III Colon Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005979
- Testing
- FOLFIRI regimen, fluorouracil, irinotecan hydrochloride
- Where
- 30 sites in France
- Sponsor
- UNICANCER
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.